22 January 2019 - Deborah Wilkes
Acquiring Nizoral and Vamousse helped lift Alliance Pharma's sales by more than a fifth in 2018.
Announcing preliminary results, Alliance Pharma said its sales in 2018 were expected to be GBP124 million (USD161 million), representing a rise of 22% as reported and 23% at constant currencies. Excluding the impact of acquisitions, sales were up by 4% as reported.
The UK-based specialty pharmaceutical company said its international star brands – Kelo-Cote, MacuShield, Nizoral and Vamousse – had "continued to perform strongly in 2018".
Sales of the scar-reduction product Kelo-Cote increased by 68% to GBP22.5 million. Alliance Pharma said there had been stronger than expected growth across the Asia-Pacific region and in mainland Europe.
The MacuShield food supplement for eyecare recorded sales up by 6% to GBP7.0 million, while sales of the head-lice treatment Vamousse, which was acquired on 28 December 2017, were up by 16% to GBP5.8 million.
Performance of Nizoral
Nizoral – the medicated anti-dandruff shampoo acquired from Johnson & Johnson (J&J) in June 2018 – generated "see-through" sales of GBP10.9 million in the second half of 2018.
Alliance Pharma said "see-through" sales included the underlying sales from Nizoral. Under the terms of the transitional services agreement with J&J, Alliance Pharma receives the benefit of the net profit on sales of Nizoral from the date of acquisition up until the product licences in the Asia-Pacific territories transfer from J&J to Alliance Pharma which is expected during 2019 and 2020.
The company acquired the rights to the Nizoral anti-dandruff shampoo in the Asia-Pacific region for GBP60.0 million (click here to read the News story).
Alliance Pharma said sales of its local brands had fallen by 5% to GBP77.8 million.
Peter Butterfield, Alliance Pharma's chief executive officer, said there had been "continued strong momentum" in the business.
Take out an Annual Subscription to the OTCToolbox website, giving you UNLIMITED ACCESS to all of our publications
* Premium News Stories
* OTCToolbox Innovations magazine NEW IDEAS BETTER WAYS
* OTCToolbox Deals Database
* News Extras
* OTC Deal Trends Briefing
* OTC Company Strategies Report
Helping you and your company make well-informed decisions
CLICK HERE TO FIND OUT MORE